Gene therapy by transforming growth factor-␤ receptor-IgG
rosis [9] . Overexpression of TGF-␤ in normal glomeruli transgene under the control of an albumin promoter/ enhancer in the transgenic mice resulted not only in hepatic fibrosis, but also in renal lesions characterized by sTransforming growth factor-␤ (TGF-␤), a multifuncprogressive mesangial expansion and tubulointerstitial tional cytokine, plays an important role in regulating fibrosis [11, 12] . Finally, fibrosis has been blocked in vivo tissue repair and remodeling following injury. One of by injection of anti-TGF-␤ neutralizing antibodies in a number of animal models, including kidney diseases [6] . These results support the hypothesis that modulation of expression by antisense oligonucleotides could suppress Here, we have examined the possibility of gene therapy to determine whether TGF␤RII/Fc could efficiently the development of experimental glomerulonephritis [13] . Furthermore, continuous delivery of decorin, which neutralize the activities of TGF-␤ in vitro and in vivo. was accomplished by in vivo gene transfer into skeletal muscle, also inhibited the extracellular matrix expansion METHODS in experimental glomerulonephritis [14] . Combined, this
Cell lines evidence strongly suggests the hypothesis that the inhibition of overexpressed TGF-␤ can ameliorate the progresThe BNul-7 mast cell line was maintained in RPMI 1640 medium supplemented with 10% fetal calf serum sion of renal diseases.
It has been shown that TGF-␤ signals are transduced (FCS), 5 ϫ 10 Ϫ5 m of 2-mercaptoethanol, 50 U/ml of penicillin, and 50 g/ml of streptomycin. Normal rat kidby simultaneously contacting two transmembrane serine/ threonine kinases known as type I and type II receptors ney (NRK) cells were propagated in Dulbecco's modified Eagle's medium supplemented with 10% FCS, 50 U/ml [15] . The type II receptor recognizes the active TGF-␤ ligand, whereas their type I receptor does not. Thus, of penicillin, and 50 g/ml of streptomycin. These cell lines were used for the growth inhibition assay and the TGF-␤ binds directly to the type II receptor, which is a constitutively active kinase. The TGF-␤-binding type II fibronectin induction assay for TGF-␤, respectively. receptor is then recognized by the type I receptor, which Construction of the chimeric gene and is recruited into the complex and becomes phosphorypurification of the chimeric molecule lated by the type II receptor. Both receptors are required for TGF-␤ action in mammalian cells [16] , because muta-
The cDNA fragment corresponding to the extracellular domain of the human TGF-␤ type II receptor gene tions in either receptor type disrupt signaling in each case. Based on the differences between their ligand-bind-(codon Ϫ7 to 480) was generated by reverse transcription-polymerase chain reaction (RT-PCR) amplification ing properties, the type II receptor acts upstream of the type I receptor, and thus, one may think of these from mRNA of HepG2 cells [19] . The primers used were 5Ј-CCACTCGAGTCTGCCATGGGTCGGGGGCTG components as primary receptor and transducer, respectively [16] . These results motivate us to produce an inacand 5Ј-CCGGGATCCAAGTCAGGATTGCTGGTGT TATATTC as sense and antisense primers, respectively. tive type II receptor construct to impede the activities of TGF-␤. However, the soluble type II receptor was For cutting out cDNA for the TGF-␤ type II receptor, Xho I and BamHI restriction sites were added to sense reported to have an approximate 10-fold lower binding affinity for TGF-␤ than does the cell-surface type II and antisense primers, respectively, as indicated by the italics. The cycling parameters were 30 seconds at 94ЊC receptor [17] . It may partly depend on the fact that the soluble type II receptor is monomeric, because the type and one minute at 68ЊC. The amplification was performed for 30 cycles by a GeneAmp PCR system 2400 II receptor found on the cell surface is primarily a homodimer and the TGF-␤ ligand is also a disulfide-linked (Perkin-Elmer Cetus Corp., Norwalk, CT, USA). The fragment was cloned into the pCRII AT cloning vector dimer.
To create an efficient inhibitor with the capacity to (Invitrogen, San Diego, CA, USA). The amplified PCR product was digested by Xho I and BamHI and inserted block the binding of TGF-␤ to type II receptor and thereby to prevent the subsequent signal transduction, into CD4Rg (a kind gift of Dr. B. Seed) from which the Xho I BamHI fragment containing the CD4 gene was we have generated a chimeric inhibitor molecule, termed TGF␤RII/Fc, in which the extracellular portion of the removed, thereby making a fusion gene between the Nterminal half of TGF-␤RII and the C-terminal half of TGF-␤ type II receptor was fused to an immunoglobulin heavy-chain Fc fragment. When expressed in mammahuman IgG1-Fc. This construct was transiently transfected by using the lian cells, TGF␤RII/Fc is expected to be secreted as a disulfide-linked homodimer. The design of this molecule diethylaminoethyl (DEAE) dextran method [20] into COS-1 cells, which were then cultured for one week was based on previous findings demonstrating that similar chimeric molecules possess functional binding sites with Dulbecco's modified Eagle's medium/F12 medium (GIBCO Laboratories, Grand Island, NY, USA) conand a markedly longer plasma half-life compared with the soluble extracellular domain [18] . Repeated injection taining 1% Nutridoma-NS (Boehringer Mannheim, Mannheim, Germany); the chimeric molecule in the culture of the purified recombinant TGF␤RII/Fc molecule may be applicable for molecular intervention of TGF-␤ acsupernatant was purified using Prosep-A (Bioprocessing, Princeton, NJ, USA). This purified chimeric molecule tion. However, the harvest of a large amount of purified TGF␤RII/Fc is expensive and time consuming. In conwas used for the in vitro study. The chimeric molecule was analyzed for purity and trast, gene transfer of TGF␤RII/Fc to the skeletal muscle is less expensive, and lasting delivery of TGF␤RII/Fc dimerization by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The purified molecule chimeric molecule could be expected. was resolved under nonreducing or reducing (with 0.715
Effects of the chimeric molecule on m of 2-mercaptoethanol) conditions in 7.5% gels. After TGF-␤'s fibronectin synthesis activity transfer to nitrocellulose membranes (Hybond-c; AmerFibronectins comprise a family of adhesive glycoprosham International, Amersham, UK), the membrane was teins that are prominent components of the mesangial blocked with phosphate-buffered saline (PBS) containextracellular matrix and are accumulated during glomering 5% (vol/vol) skim milk and 1% bovine serum albuular injury. There are several forms of fibronectins that min, incubated with horseradish peroxidase-conjugated differ in their primary structure by the alternative splicavidin (Bio-Rad, Richmond, CA, USA), and developed ing of a unique mRNA precursor (pre-mRNA) tranusing the enhanced chemiluminescence (ECL) detection scribed from a single gene; three sites of alternative splicreagent (Amersham Corp., Arlington Height, IL, USA).
ing have so far been described-ED-A, ED-B, and Because the extracellular domain of TGF-␤ type II re-IIICS-in human fibronectins and the corresponding receptor has three glycosylation sites, the reduced chimeric gions-EIIIA, EIIIB, and V-in rat fibronectins [22, 23] . molecule was also deglycosylated by N-glycosidase to Fibronectin mRNA containing EIIIA exon has been readdress whether this chimeric molecule could be an exported to increase along with the severity of the disease pected size. After reducing the chimeric molecule, 10 g in response to TGF-␤ [24] . of chimeric molecule were incubated with or without 0.4
To study the effects of the chimeric molecule on the units of N-glycosidase F (Boehringer Mannheim) at 37ЊC alternative splicing of fibronectins pre-mRNA induced overnight. Untreated chimeric molecule and chimeric by TGF-␤, we designed specific probes complementary molecule treated with or without N-glycosidase F were to the sequence of pre mRNA encompassing the EIIIA analyzed through 4% to 20% SDS-PAGE. After transfer exon for RT-PCR (Fig. 3A) . The primers used were 5Ј-to nitrocellulose membranes, the membrane was incu-AGAACCGGAACGGAGAAAGC-3Ј and 5Ј-GAGGT bated with antihuman TGF-␤ type II receptor antibody GCTGTCTGGAGAAAG-3Ј as the sense and antisense (R&D Systems Inc., Minneapolis, MN, USA) for one hour primers, respectively. The amplified fragments were deand then labeled with horseradish peroxidase-conjugated tected as 484 bp and 214 bp for EIIIA positive and EIIIA antigoat IgG (Santa Cruz, Biotechnology Inc., Santa Cruz, negative exons, respectively. CA, USA). The membrane was washed and was then One ϫ 10 5 NRK cells were plated in Dulbecco's modideveloped using the ECL detection reagent (Amersham).
fied Eagle's medium with 10% FCS in a 25 cm 2 culture For in vivo study, pCAGGS-TGF␤RII/Fc was conflask and were then grown to the confluency. The constructed by inserting the Xho I-Xma III fragment confluent NRK cell layer was either left untreated or intaining a fusion gene into the Xho I site of pUC-CAGGS cubated with 1 ng/ml of TGF-␤ and/or 10 g/ml of [21], which contains the cytomegalovirus enhancer and TGF␤RII/Fc by placing them in fresh medium for two the chicken ␤-actin promoter.
days. After 48 hours of exposure, the cells were washed with PBS, and mRNA was extracted by a QuickPrep
Effects of the chimeric molecule on TGF-␤'s growth inhibition activity
Micro mRNA Purification kit (Quiagen, Hilden, Germany). The mRNA concentrations were determined usOne ϫ 10 3 of BNul-7 cells in 96-well culture plates were ing spectrophotometric readings at Absorbance 260. The cultured with various concentrations of TGF-␤1 (0.01 synthesis of cDNA was carried out in a 20 l reaction ng/ml to 1.25 ng/ml) in the presence or the absence of volume containing 0.5 g RNA from NRK cells, 0.5 mm chicken anti-TGF-␤ antibodies (1.25 g/ml; R&D SysdNTPs, 1 ϫ RT buffer (GIBCO), 0.5 g/ml Oligo dT tems) or chimeric TGF␤RII/Fc (1.25 g/ml) for three 12-18 random primers, 10 mm dithiothreitol, and 20 U days. Then, the BNul-7 cell growth was measured by murine leukemia virus (MLV) reverse transcriptase the 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrozolium (GIBCO) incubated for one hour at 42ЊC. One microliter bromide (MTT; Sigma Chemical Co., St. Louis, MO, of this mixture was incubated in a 50 l volume reaction USA) assay. Twenty micrograms of MTT at 5 mg/ml in with 50 pmol of primers, 0.2 mol of each dNTP, and PBS was added to each 100 l of culture medium. After 2.5 U Taq polymerase (Perkin-Elmer Cetus Corp.) and incubation for an additional five hours at 37ЊC, the subjected to 25 cycles of PCR, each consisting of one formazan crystals were dissolved by the addition of 100 minute at 94ЊC, two minutes at 60ЊC, and three minutes l of 10% SDS in 0.01 n HCl. The plates were then at 72ЊC. The amplified fragments (484 bp and 214 bp for incubated overnight, and the optical density of the wells EIIIA positive and EIIIA negative, respectively) were was determined using Multiskan (Labsystems, Helsinki, analyzed by electrophoresis on agarose gels. Finland) at a wavelength of 620 nm. Within at least one hour, the plates were read on a micro-enzyme-linked Preparation of hemagglutinating virus of immunosorbent assay reader at a wavelength of 570 nm Japan liposome and a reference wavelength of 620 nm. The results of
The chimeric TGF␤RII/Fc gene was transfected to the the inhibition studies are presented as a percentage of TGF-␤-free proliferation of BNul-7 cells.
gluteal muscle of nephritic rats by the of hemagglutinat-ing virus of Japan (HVJ) liposome gene transfer method Detection of chimeric gene expression [10, 13, 14] , which has been employed for transient transTotal RNA was isolated from the skeletal muscle of fection in vivo. The HVJ liposomes were prepared as TGF␤RII/Fc gene-transferred nephritic rat, and the isodescribed previously [10, 13, 14] . Briefly, phosphatidyllated RNA was subsequently reversed transcribed into serine, phosphatidylcholine, and cholesterol were mixed cDNA. To examine the expression of chimeric gene, sense in a weight ratio of 1:4.8:2. Dried lipid was hydrated in and antisense primers were designed from the cDNA se-200 l of balanced salt solution (BSS) containing 200 quences of the extracellular domain of the TGF-␤ type g of pCAGGS-TGF␤IIR/Fc, vortexed vigorously, and II receptor and IgG-Fc hinge region, respectively. The primers used were 5Ј-TCCTGTGGACGCGTATCGC-3Ј sonicated to form liposomes. The liposomes were incuand 5Ј-GAGTTTTGTCACAAGATTTGGG-3Ј as the bated with purified HVJ inactivated by ultraviolet irradisense and antisense primers, respectively. The amplified ation (110 erg/mm 2 /sec) for three minutes just before fragment was detected as 420 bp for spliced TGF␤RII/ use. The liposome suspensions (containing 10 mg of lipids) Fc mRNA. were mixed with HVJ (30,000 hemagglutinating units) in Three days after transfection, untreated nephritic rats a total volume of 2 ml BSS. The mixture was incubated and TGF␤RII/Fc gene-transfected rats were sacrificed, at 4ЊC for 10 minutes and was gently shaken for 60 minutes and then the kidneys were removed and were fixed in at 37ЊC. Free HVJ was removed from the HVJ liposomes methylcarn solution. Glomerular deposition of TGF␤RII/ by discontinuous density gradient centrifugation with suFc molecule was stained with the monoclonal antibody crose. The HVJ-liposome suspension contained approxito human IgG-Fc (Caltag Laboratories, San Francisco, mately 20 g of pCAGGS-TGF␤RII/Fc in 1 ml BSS and CA, USA). was maintained at 4ЊC.
Glomerular RNA preparation and In vivo experimental design
Northern blot analysis On day 0, to induce anti-Thy-1 model of experimental
To examine the effects on the level of TGF-␤1 and glomerulonephritis, the anti-Thy-1 antibody OX-7 (1.0 type I collagen mRNA, Northern blot analysis was permg/kg; a gift from Dr. Kenichi Isobe and Dr. Seiichi formed with glomerular RNA extracted from nephritic Matsuo, Nagoya University, Japan) was administrated rats treated with 0 g, 5 g, or 20 g of pCAGGSintravenously to six-week-old male Sprague-Dawley rats TGF␤RII/Fc chimeric gene transfection. Six days after (Japan SLC, Inc., Hamamatsu, Japan). On day 1, netransfection (seven days after disease induction), total phritic rats were anesthetized by ether, and the left glu-RNA was prepared from pooled glomeruli that were teal muscles were exposed. HVJ-liposome solutions enisolated from the minced kidneys of six rats together in capsulating 0 g, 5 g, or 20 g of pCAGGS-TGF␤RII/ each group by the graded sieving technique as described Fc were then injected into the gluteal muscles of the previously [13, 14] . For the Northern blot analysis, 20 nephritic rats. Three days after transfection, three ung aliquots of total RNA were separated on 1% agarose formaldehyde gel and were transferred onto nylon memtreated nephritic rats and three TGF␤RII/Fc gene-transbranes (Hybond-N; Amersham). TGF-␤1, type I collaferred nephritic rats were sacrificed, and kidney and skelgen, and GAPDH cDNA [13, 25] were labeled by the etal muscle were removed to examine the expression of random priming method using [␣-32 P] dATP (3000 Ci/ chimeric gene. On day 7, the kidneys from six untreated mmol; Amersham). Hybridization was carried out at 42ЊC nephritic rats and six of the 5 g or 20 g of pCAGGSovernight in 50% formamide, 10 ϫ Denhardt's solution, TGF␤RII/Fc gene-transfected nephritic rats were per-1% SDS, 5 ϫ SSC, 50 mm Na phosphate, and 200 g/ml fused with cold autoclaved PBS, and samples of the corsalmon sperm DNA. The blots were washed three times tex were taken for histology. Tissues for light microscopy at 50ЊC in 0.5 ϫ SSC and 0.1% SDS, and the signals were fixed with 4% paraformaldehyde overnight and were quantitated by laser densitometry (ScanningImager; dehydrated through a graded ethanol series and embedMolecular Dynamics, Sunnyvale, CA, USA). ded in paraffin. Histologic sections (2 m) of kidneys were stained with periodic acid-Schiff reagent. To quanStatistical analysis titate mesangial matrix accumulation, all sections were All values are expressed as mean Ϯ se. Statistical evaluated by an observer unaware of the experimental significance (defined as P Ͻ 0.01) was evaluated using protocol. Thirty glomeruli were selected at random in the one-way analysis of variance. cross-sections from each rat. The degree of mesangial matrix accumulation was determined as the percentage RESULTS of each glomerulus occupied by the mesangial matrix Purification of TGF␤RII/Fc as described previously [13, 14] . For glomerular RNA preparations, glomeruli were isolated from the re-TGF␤RII/Fc was created by cDNA encoding the extracellular domain of the human TGF-␤ type II receptor maining tissue by a standard sieving method. 65 kDa. Both samples migrate considerably higher on the gels than their predicted molecular weight (45 kDa). However, deglycosylating the chimeric molecule using N-glycosidase altered the molecular weight to 45 kDa, ligated to the cDNA for the Fc portion of the human IgG1 heavy chain. The immunoglobulin portion of this suggesting that this chimeric molecule was secreted after glycosylation (Fig. 2) . fusion molecule contains the hinge and constant region CH2 and CH3 domains. These fusion molecules lack Effects of the chimeric molecule on the TGF-␤ type II receptor transmembrane domain but TGF-␤'s growth-inhibition activity contain the IgG heavy-chain hinge region Cys residues and, therefore, should be secreted from cells as a soluble
To characterize the in vitro properties of the chimeric molecule consisting of the TGF-␤ type II receptor fused dimer.
Based on the primary structure of the extracellular to the IgG-Fc domain, the recombinant chimeric molecule was purified. Because the TGF␤RII/Fc chimeric domain connected with the IgG-Fc molecule, our model predicts that these molecules will behave as homodimers, molecule was expected to act as a competitive antagonist for TGF-␤, we assessed whether the recombinant chimeby virtue of the IgG hinge region. Analysis of the purified molecules by SDS-PAGE under both reducing (with ric TGF␤RII/Fc molecule could attenuate the effects of TGF-␤ on the growth-inhibiting action. To test this 0.715 m of 2-mercaptoethanol) and nonreducing conditions demonstrates the purity of the preparations and possibility, BNul-7 cells, which express the native TGF-␤ receptors, were treated with TGF-␤1, and cell growth confirms the predicted homodimer structure of the native chimeric molecules (Fig. 1) . Under nonreducing conwas measured by an MTT assay in the presence of either TGF␤RII/Fc (1.25 g/ml) or anti-TGF-␤ antibodies ditions, the TGF␤RII/Fc chimeric molecule is estimated
Detection of chimeric gene expression
To show the feasibility of the chimeric gene transfer into muscle, we examined the TGF␤RII/Fc gene expression in the transfected muscle by using the specific primers encompassing the extracellular domain of the TGF-␤ type II receptor and IgG-Fc hinge region (Fig. 5A) . Amplification with the specific primer set revealed the presence of transcript for the 420 bp product in the cDNA obtained from TGF␤RII/Fc-transfected muscle (lane 1). However, an extract from TGF␤RII/Fc transfected muscle (without reverse transcription; lane 2) did not result in a 420 bp product. gial area three days after transfection (Fig. 5B) , whereas concentrations from 0.01 ng/ml to 1.25 ng/ml of TGF-␤, the growth of there was no deposition in the glomeruli of untreated BNul-7 cells was inhibited by TGF-␤1 in a dose-dependent manner. Both anti-TGF-␤ antibodies and chimeric TGF␤RII/Fc completely disease control rats (Fig. 5C ).
blocked the growth inhibitory action of TGF-␤1.
Inhibition of TGF-␤1 expression in nephritic glomeruli (1.25 g/ml). At concentrations from 0.01 ng/ml to 1.25
Given the competitive properties of chimeric TGF␤RII/ ng/ml of TGF-␤, the growth of BNul-7 cells was inhibited Fc against TGF-␤1 in vitro, we assessed the feasibility by TGF-␤1 in a dose-dependent manner. Both antiof chimeric gene transfer in vivo. HVJ-liposome solution TGF-␤ antibodies (1.25 g/ml) and chimeric TGF␤RII/ containing 5 g or 20 g of pCAGGS-TGF␤RII/Fc was Fc (1.25 g/ml) completely blocked the growth inhibitory introduced into the gluteal muscles of nephritic rats one action of TGF-␤1 (Fig. 3) .
day after injection of the OX-7 antibody. HVJ-liposome solution without DNA was also examined in nephritic Effects of the chimeric molecule on rats as untreated disease controls. On day 7, we obtained TGF-␤'s matrix-synthesis activity glomerular RNA to examine whether the chimeric For an alternative approach to identifying the proper-TGF␤RII/Fc gene transfection could reduce the message ties of TGF␤RII/Fc as a competitive antagonist for of TGF-␤1 and type I collagen in glomeruli. Glomeruli TGF-␤1, we addressed whether recombinant chimeric were isolated by the graded sieving technique, and TGF␤RII/Fc molecule could manipulate the effects of Northern blot analysis was performed to compare the TGF-␤ on the extracellular matrix synthesis. NRK cells levels of TGF-␤1 and type I collagen mRNA. The were treated with TGF-␤1 (1 ng/ml), and the expression TGF-␤1 and type I collagen mRNA levels were elevated of fibronectin EIIIA was measured in the presence or by more than 10-and 12-fold in untreated disease conabsence of TGF␤RII/Fc (10 g/ml). Alternative splicing trols seven days after OX-7 injection, respectively. Laser at EIIIA exon generates two types of fibronectin mRNA densitometric analysis revealed that TGF-␤1 mRNA exthat differ in terms of the presence or absence of the pression in glomeruli from nephritic rats transfected with EIIIA sequences. The two fibronectin mRNA variants 5 g and 20 g of the chimeric gene was reduced to 48% EIIIAϩ (with EIIIA exon) and EIIIAϪ (without EIIIA and 39% of that in untreated disease controls, respecexon) were examined by the RT-PCR method. EIIIAϩ tively (Fig. 6 ). The effect of TGF␤RII/Fc transfection fibronectin is considered to be a specific marker for on type I collagen mRNA expression was observed as TGF-␤ activity and matrix accumulation, because it is a similar pattern. The level of GAPDH mRNA remained almost undetectable in normal adult rat glomeruli and unaffected in all transfected kidneys. is strongly induced by TGF-␤ [24] .
Exposed to TGF-␤1, EIIIAϩ fibronectin mRNA inSuppression of extracellular matrix expansion in creased over control NRK cells, whereas EIIIAϪ fibronephritic glomeruli nectin mRNA increased slightly. There was a clear reGiven the effective suppression of TGF-␤1 message duction in EIIIAϩ after treatment with the purified production, we assessed the inhibitory action of chimeric chimeric molecule even though the reduction of EIIIAϪ gene transfection on the histologic changes in the kidney was much less dramatic (Fig. 4) . Thus, the chimeric on day 7. Figure 7 shows the representative appearance TGF␤RII/Fc molecule also inhibits the TGF-␤-induced extracellular matrix synthesis.
of the glomeruli. In the kidneys from the untreated ne- phritic rats, the glomeruli exhibited marked increases in the pathogenesis of human and experimental glomerular mesangial extracellular matrix. In contrast, chimeric disease [1, 2, 7, 8, 11, 12] . In conditions characterized by gene transfection markedly suppressed the increase in chronic inflammation and fibrosis caused by overpromesangial matrix expansion. Semiquantitative analysis duced TGF-␤, blocking the action of TGF-␤ seems very of mesangial matrix indices is summarized in Figure 8 .
promising. Therefore, there is considerable interest in The mesangial matrix indices of glomeruli from the kidpotential therapeutic applications to manipulate TGF-␤ neys untransfected, 5 g transfected, and 20 g transactions in glomerular disease by gene therapy. It seems fected were 3.1 Ϯ 0.4, 2.1 Ϯ 0.5, and 1.9 Ϯ 0.6, respecthat there are two clear possible therapeutic strategies tively. These results demonstrated that chimeric TGF␤RII/ for decreasing the action of TGF-␤ that may be more Fc gene transfer one day after disease induction could suitable than antibodies in humans. We have been acsuppress extracellular matrix expansion.
tively investigating the potential of molecular biological intervention to antagonize the action of TGF-␤ in glomerular diseases in two ways: One strategy is a direct DISCUSSION inhibition of TGF-␤ synthesis by application of antisense Transforming growth factor-␤ is a key cytokine in oligodeoxynucleotides [13] , and the other is gene transfer which its actions in promoting the production and depoof an inhibitory molecule against TGF-␤, such as decorin, sition of extracellular matrices are essential for normal a small proteoglycan, by competitively blocking the actissue repair following injury, and sustained or excessive expression of TGF-␤ is considered to be clearly causal in tive TGF-␤ binding to the cognate receptor [14] . In this study, we generated a fusion protein in which TGF-␤ type II receptor cDNA encoding extracellular domain was recombined in frame with the Fc portion of the human immunoglobulin IgG1 heavy-chain cDNA at the hinge region. Because of the T-cell receptor and CD4 immunoadherin fusion proteins [18] , receptor-IgG chimeras have been used for structural and functional studies of the Ig-like superfamily of receptors, including c-kit [26] and the platelet-derived growth factor receptor [27] . The ligand-binding properties of other non-Ig-like receptors, including the natriuretic peptide receptors [28] , tumor necrosis factor receptor [29] , and hepatocyte growth factor receptor [30] , have been analyzed by means of secreted immunoglobulin fusion proteins as well. It was reported that dimeric tumor necrosis factor receptor-IgG heavy-chain chimeric protein was quite effective as a tumor necrosis factor inhibitor. In contrast, the monovalent extracellular portion had a greatly reduced tumor necrosis factor inhibitory activity compared with that of the bivalent inhibitor [29] . Therefore, we in BNul-7 cells (Fig. 3) , and (b) recombinant chimeric TGF␤RII/Fc protein (10 g/ml) diminished EIIIAϩ mRNA induced by TGF-␤ (1 ng/ml) below the control level of untreated NRK cells (Fig. 4) .
The chimeric-soluble TGF-␤ receptor is a secreted protein, and when the expression vector is transferred in the skeletal muscle, soluble TGF-␤ receptors would be expected to increase the secretion and delivery to the kidneys via the bloodstream in the context of a disulfidelinked dimer. RT-PCR analysis of the chimeric gene-transfected muscle demonstrated that processed TGF␤RII/Fc mRNA was expressed three days after transfection ( tage for in vivo studies because of its extended plasma half-life [18] . It would thus appear that adding an IgG heavy chain as a partner in chimeric molecules may be ligand of TGF-␤. In fact, SDS-PAGE analysis demona useful strategy for the expression of molecules that strated that TGF␤RII/Fc is processed to a two-chain would otherwise prove unstable in circulation. form when expressed in COS cells such as the cell-associ-
The phenomenon of protein deposition in the glomerated TGF-␤ type II receptor (Fig. 1) . Our data confirmed ulus is well known and has been extensively studied. that indeed, recombinant chimeric TGF␤RII/Fc was a Deposition of the molecule in the glomerulus depends competitive antagonist of TGF-␤ in two ways: (a) Reon the size and charge of the molecule, and the capability combinant chimeric TGF␤RII/Fc (1.25 g/ml) comof the molecule phagocytosed/endocytosed by mesangial cells. Anionic antigens or antigens with a large size have pletely blocked the growth inhibitory action of TGF-␤ a tendency to form deposits in the mesangium. Large contents, but identical tensile strength and more normal dermal architecture than the other wounds. We have particles may enter the mesangium through fenestrated endothelium. It remains unclear why the large size and seen no such adverse effects in our work with chimeric gene transfer. Extreme reduction of TGF-␤ levels may anionic property of the molecule determine its mesangial localized deposition; however, it may be feasible that a be pathological; however, our results show that chimeric gene transfer suppressed TGF-␤1 mRNA expression, portion of the molecule enables the specific delivery to the mesangium. Employing this concept (delivering a spebut the level of TGF-␤1 was over the normal level, and it is unlikely that gene transfer renders cells unresponsive cific molecule into the glomerulus via gene transfer to a nonrenal organ) we have already shown that the decorin to normal signal transduction of TGF-␤1. For these reasons, we feel that suppressing TGF-␤ with chimeric gene secreted from the transfected muscle could target the glomerulus and block the fibrotic actions of TGF-␤ [14] .
therapy will be safe. However, the long-term consequences of reducing TGF-␤ levels are unknown, and the Here, it was also shown that the chimeric TGF␤RII/Fc molecule was detected in the mesangial area (Fig. 5B) , possibility of adverse effects must be carefully studied. indicating that TGF␤RII/Fc was produced in the muscle
In conclusion, we constructed a chimeric molecule deand delivered to the kidney. signed specifically to inhibit TGF-␤-mediated glomerular Of interest is that chimeric TGF␤RII/Fc treatment matrix accumulation. The TGF␤RII/Fc binds TGF-␤1, reduced the increase in TGF-␤1 mRNA levels. This findthereby blocking the biological activities of TGF-␤ in ing strongly supports the hypothesis that a positive feedvitro. Moreover, the transfection of the TGF␤RII/Fc back system exists for stimulation of TGF-␤ production gene into the muscles of nephritic rats prevented glomerby TGF-␤, by itself, in glomeruli [31] and that the binding ular matrix expansion in vivo. These results suggest that of TGF-␤ to a chimeric TGF␤RII/Fc intercepted the TGF␤RII/Fc may prove to be clinically useful, given positive feedback pathway. These results suggest that the that blocking of TGF-␤ overexpression in the glomeruli characteristic features of glomerular lesions are largely provides a potentially powerful therapeutic approach to mediated by increased endogenous TGF-␤ activity in the treatment of TGF-␤-mediated glomerular diseases. the kidney and that these manifestations can also be attenuated by blocking TGF-␤. ACKNOWLEDGMENTS The HVJ liposome-mediated transfer of a TGF-␤ in-
